Therefore, we sought to explore the relationship between activation and compartmentalization of Akt1 and Akt2 and the outcome of targeted therapy in a sample of patients with metastatic HER2-positive breast cancer treated with trastuzumab. Here, ERBB2 is linked to breast carcinoma.